Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ibrance® Post-Marketing Database Study Incidence of Interstitial Lung Disease in Inoperable or Recurrent Breast Cancer Patients Treated With Palbociclib in a Post-marketing Setting: Cohort Study Using the Medical Data Vision (MDV) Database

NCT07096024 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07096024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07096024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ibrance® Post-Marketing Database Study Incidence of Interstitial Lung Disease in Inoperable or Recurrent Breast Cancer Patients Treated With Palbociclib in a Post-marketing Setting: Cohort Study Using the Medical Data Vision (MDV) Database
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
January 21, 2025
Completion date
February 7, 2025
Enrollment
95,637 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms